SOAT1 and tuberculosis: Although JAK/STAT inhibitors provide therapeutic benefit in a variety of diseases, their use in patients with latent tuberculosis requires careful consideration, comprehensive screening, and vigilant monitoring to reduce the risk of tuberculosis reactivation.